L3VLUP
ProSign in

SNY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SNYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SNY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterSNYJNJ
Q3 202011 holders, $3.4bn30 holders, $26.2bn
Q4 20207 holders, $3.3bn32 holders, $26.6bn
Q1 20217 holders, $4.5bn31 holders, $25.3bn
Q2 20215 holders, $4.9bn37 holders, $25.6bn
Q3 20217 holders, $6.0bn40 holders, $24.1bn
Q4 20217 holders, $6.2bn33 holders, $25.2bn
Q1 20227 holders, $6.5bn35 holders, $28.2bn
Q2 20227 holders, $6.1bn33 holders, $26.9bn
Q3 20229 holders, $4.6bn36 holders, $25.4bn
Q4 202210 holders, $5.9bn35 holders, $27.6bn
Q1 202312 holders, $6.6bn42 holders, $24.5bn
Q2 20239 holders, $6.1bn38 holders, $25.0bn
Q3 20239 holders, $5.9bn37 holders, $18.9bn
Q4 20237 holders, $5.3bn31 holders, $19.0bn
Q1 20247 holders, $5.1bn32 holders, $19.7bn
Q2 202411 holders, $5.5bn35 holders, $20.4bn
Q3 202411 holders, $6.5bn28 holders, $22.3bn
Q4 20248 holders, $5.1bn37 holders, $20.4bn
Q1 20258 holders, $6.2bn32 holders, $20.5bn
Q2 20257 holders, $4.8bn31 holders, $18.4bn
Q3 20256 holders, $3.8bn32 holders, $23.7bn
Q4 20256 holders, $3.0bn29 holders, $27.8bn
Q1 20266 holders, $1.7bn34 holders, $35.6bn
Q2 20267 holders, $1.6bn33 holders, $39.1bn
SNY

Sanofi

Holders
11
Reported value
$6.5bn
Buyers
5
Sellers
7

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
28
Reported value
$22.3bn
Buyers
13
Sellers
16

Breadth -3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SNY (4)

Balyasny Asset Management LLC, First Eagle Investment Management LLC, Millennium Management LLC, Soros Fund Management LLC

Only JNJ (21)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, GAMCO Investors Inc, Holocene Advisors LP, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →